Nektar Therapeutics (NKTR)
Largest Insider Buys in Sector
NKTR Stock Price History Chart
NKTR Stock Performance
About Nektar Therapeutics
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in areas of unmet medical need in the United States and internationally. The company's products include Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in phase 3 clinical trial to treat metastatic melanoma, renal cell carcinoma, muscle-invasive bladder cancer, squamous cell carcinoma of the head and neck, and adjuvant melanoma; phase 2 clinical trial for the treatment of renal cell carcinoma, non-small cell …
Insider Activity of Nektar Therapeutics
Over the last 12 months, insiders at Nektar Therapeutics have bought $0 and sold $253,971 worth of Nektar Therapeutics stock.
On average, over the past 5 years, insiders at Nektar Therapeutics have bought $0 and sold $5.61M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 15,000 shares for transaction amount of $259,200 was made by Doberstein Stephen K (SVP & Chief Scientific Officer) on 2019‑09‑05.
List of Insider Buy and Sell Transactions, Nektar Therapeutics
| 2024-08-19 | Sale | President & CEO | 14,881 0.0078% | $1.28 | $19,048 | -3.76% | ||
| 2024-08-19 | Sale | Chief R&D Officer | 6,866 0.0036% | $1.28 | $8,788 | -3.76% | ||
| 2024-08-19 | Sale | Chief Legal Officer | 5,651 0.003% | $1.28 | $7,233 | -3.76% | ||
| 2024-06-14 | Sale | director | 19,500 0.0101% | $1.20 | $23,400 | +8.55% | ||
| 2024-05-17 | Sale | President & CEO | 16,650 0.0087% | $1.75 | $29,138 | -27.27% | ||
| 2024-05-17 | Sale | Chief R&D Officer | 7,355 0.0039% | $1.75 | $12,871 | -27.27% | ||
| 2024-05-17 | Sale | Chief Legal Officer | 6,260 0.0033% | $1.75 | $10,955 | -27.27% | ||
| 2024-05-10 | Sale | 10 percent owner | 56,000 0.0308% | $1.78 | $99,630 | -26.29% | ||
| 2024-02-20 | Sale | President & CEO | 20,033 0.0107% | $0.68 | $13,622 | +92.13% | ||
| 2024-02-20 | Sale | Chief R&D Officer | 9,014 0.0048% | $0.68 | $6,130 | +92.13% | ||
| 2024-02-20 | Sale | Chief Legal Officer | 7,606 0.0041% | $0.68 | $5,172 | +92.13% | ||
| 2023-11-17 | Sale | President & CEO | 19,877 0.0105% | $0.49 | $9,740 | +138.78% | ||
| 2023-11-17 | Sale | Chief R&D Officer | 9,646 0.0051% | $0.49 | $4,727 | +138.78% | ||
| 2023-11-17 | Sale | Chief Legal Officer | 7,179 0.0038% | $0.49 | $3,518 | +138.78% | ||
| 2023-09-18 | Sale | director | 4,359 0.0023% | $0.69 | $3,008 | +24.09% | ||
| 2023-09-18 | Sale | director | 4,359 0.0023% | $0.69 | $3,008 | +24.09% | ||
| 2023-08-16 | Sale | President & CEO | 19,998 0.0107% | $0.78 | $15,598 | -11.31% | ||
| 2023-08-16 | Sale | Chief R&D Officer | 9,703 0.0052% | $0.78 | $7,568 | -11.31% | ||
| 2023-08-16 | Sale | Chief Legal Officer | 7,221 0.0039% | $0.78 | $5,632 | -11.31% | ||
| 2023-06-14 | Sale | director | 30,000 0.0164% | $0.57 | $17,100 | +8.29% |
Insider Historical Profitability
| ROBIN HOWARD W | President & CEO | 848358 0.4609% | $1.39 | 1 | 76 | <0.0001% |
| WHITFIELD ROY A | director | 216250 0.1175% | $1.39 | 3 | 2 | +51.06% |
| GREER R SCOTT | director | 176574 0.0959% | $1.39 | 1 | 5 | +42.48% |
| Doberstein Stephen K | SVP & Chief Scientific Officer | 107668 0.0585% | $1.39 | 1 | 20 | +17.27% |
| WINGER DENNIS L | director | 42750 0.0232% | $1.39 | 1 | 4 | +8.33% |
Institutional Investor Ownership
| Deep Track Capital Lp | $17.19M | 10.02 | 18.4M | 0% | +$0 | 0.08 | |
| The Vanguard Group | $11.26M | 6.56 | 12.05M | +0.05% | +$5,852.76 | <0.0001 | |
| Acadian Asset Management | $7.07M | 4.12 | 7.57M | -3.19% | -$233,274.43 | 0.03 | |
| PRIMECAP Management Co | $6.51M | 3.79 | 6.97M | -0.5% | -$32,790.42 | 0.01 | |
| BlackRock | $5.49M | 3.2 | 5.88M | -3.7% | -$211,058.19 | <0.0001 |